Abstract
There is a family of proteins - integrins, which are generally expressed at low levels on epithelial cells and mature endothelial cells, but they are highly expressed on the surface of both endothelial cells in tumor neovasculature and some tumor cells, including osteosarcomas, neuroblastomas, glioblastomas, melanomas, and carcinomas of the lung, the breast, the prostate, and the bladder. The alpha(v)beta(3) integrin plays a critical role in angiogenesis and tumor metastasis. Angiogenic blood vessels overexpress alpha(v)beta(3) integrin, as in tumor neovascularization, while alpha(v)beta(3) integrin expression in other microvascular beds and organs is limited. Therefore, alpha(v)beta(3) integrin is a suitable receptor for tumor-targeting therapy and imaging. The alpha(v)beta(3) integrin-targeting properties and the therapeutic potential of various radiolabeled RGD peptides are herein discussed.
Keywords: Integrin, alpha(v)beta(3), RGD peptide, therapy, imaging
Current Radiopharmaceuticals
Title: Advances in α(v)β(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides
Volume: 2 Issue: 3
Author(s): Petar M. Mitrasinovic
Affiliation:
Keywords: Integrin, alpha(v)beta(3), RGD peptide, therapy, imaging
Abstract: There is a family of proteins - integrins, which are generally expressed at low levels on epithelial cells and mature endothelial cells, but they are highly expressed on the surface of both endothelial cells in tumor neovasculature and some tumor cells, including osteosarcomas, neuroblastomas, glioblastomas, melanomas, and carcinomas of the lung, the breast, the prostate, and the bladder. The alpha(v)beta(3) integrin plays a critical role in angiogenesis and tumor metastasis. Angiogenic blood vessels overexpress alpha(v)beta(3) integrin, as in tumor neovascularization, while alpha(v)beta(3) integrin expression in other microvascular beds and organs is limited. Therefore, alpha(v)beta(3) integrin is a suitable receptor for tumor-targeting therapy and imaging. The alpha(v)beta(3) integrin-targeting properties and the therapeutic potential of various radiolabeled RGD peptides are herein discussed.
Export Options
About this article
Cite this article as:
Mitrasinovic M. Petar, Advances in α(v)β(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides, Current Radiopharmaceuticals 2009; 2 (3) . https://dx.doi.org/10.2174/1874471010902030214
DOI https://dx.doi.org/10.2174/1874471010902030214 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aurora B Kinase and Passenger Proteins as Targets for Cancer Therapy
Current Enzyme Inhibition The Use of the Bone Seeking Radiopharmaceutical 153-Samarium-EDTMP as an Adjuvant Treatment for Osteosarcoma: A Review
Current Medical Imaging Two Key Challenges for Effective Adenovirus-Mediated Liver Gene Therapy:Innate Immune Responses and Hepatocyte-Specific Transduction
Current Gene Therapy The Mad2-Binding Protein p31<sup>comet</sup> as a Potential Target for Human Cancer Therapy
Current Cancer Drug Targets Effects of Hyperlipidemia and Cardiovascular Diseases on Proliferation, Differentiation and Homing of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Is There an Increased Risk of Lymphoma and Malignancies Under Anti- TNF Therapy in IBD?
Current Drug Targets Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Topics of Physiological and Pathophysiological Functions of Lymphatics
Current Molecular Medicine Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists
Anti-Cancer Agents in Medicinal Chemistry Natural Compounds with Cell Growth Inhibitory Activity in Human Tumor Cell Lines
Anti-Cancer Agents in Medicinal Chemistry RAGE: A Single Receptor for Several Ligands and Different Cellular Responses: The Case of Certain S100 Proteins
Current Molecular Medicine Identification of Novel Antagonists for Rab38 Protein by Homology Modeling and Virtual Screening
Combinatorial Chemistry & High Throughput Screening MicroRNA in Implant Dentistry: From Basic Science to Clinical Application
MicroRNA Clustering and Sampling of the c-Met Conformational Space: A Computational Drug Discovery Study
Combinatorial Chemistry & High Throughput Screening Recent Patents on MicroRNA-Induced Pluripotent Stem Cell Generation
Recent Patents on Regenerative Medicine Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy TGF-β Pathway as a Therapeutic Target in Bone Metastases
Current Pharmaceutical Design Tamoxifen in the Treatment of Hepatocellular Carcinoma: 5-Year Results of the CLIP-1 Multicentre Randomised Controlled Trial
Current Pharmaceutical Design Folate-Linked Lipid-Based Nanoparticle for Targeted Gene Delivery
Current Drug Delivery Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets